OPKO Health Projects FY 2026 Revenue of $268M-$278M Following LabCorp Asset Sale
OPKO Health (OPK) has announced a strategic shift following an agreement to sell assets to LabCorp for $722 million. This transaction is intended to facilitate the company's complete exit from the clinical laboratory services sector, allowing management to refocus resources and capital on core business areas. Following the divestiture, OPKO projects continuing-operations revenue for fiscal year 2026 to be between $268 million and $278 million. The move is described by management as a defining moment that will sharpen the company's operational focus.
Topics: clinical laboratory services divestiture earnings call strategic restructuring
Read the full article at Seeking Alpha
Part of the story Heritage Global Reports Q3 2026 Revenue Growth Amid Strategic Shift to Asset-Light Model (7 articles)